Armaviscon Chondro 3 ml

– for symptomatic treatment of mild, moderate or severe osteoarthritis;
– to increase joint mobility and relieve pain caused by degenerative-dystrophic or post-traumatic joint changes;
– for rehabilitation after arthroscopy;
– for treatment of patients with increased physical activity and who regularly load the affected joint.

Indications

– for the symptomatic treatment of mild, moderate or severe osteoarthritis;
– to increase joint mobility and eliminate pain caused by degenerative-dystrophic or post-traumatic changes in joints;
– for rehabilitation after arthroscopy;
– for the treatment of patients who have increased physical activity and regularly load the affected joint.

Special instructions

Sodium hyaluronate is obtained by fermentation of Streptococcus equi bacteria and is carefully purified. However, the physician must consider the potential risks associated with injecting any biological substance.
During the first 2 days after the procedure, it is recommended not to overload the joint, especially prolonged loading should be avoided.
Armaviscon® Chondro does not affect a person’s ability to drive vehicles or engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
For one time use only.
The kit may include 2 disposable sterile injection needles so that the doctor can select a needle of the required caliber/size depending on the joint into which the solution will be injected.
Be sure to pay attention to the expiration date of the needle indicated on its label.
Follow national and local rules and regulations to ensure safe use and disposal of used needles.

Composition

Composition per 1 ml: sodium chondroitin sulfate – 30.0 mg, sodium hyaluronate – 20.0 mg, sodium citrate dihydrate – 8.63 mg, anhydrous citric acid – 4.89 mg, sodium chloride – 2.1 mg, 10 M sodium hydroxide solution – to pH 6.4-7.6, water for injection – up to 1 ml.
The dynamic viscosity of the solution is more than 2000 mPa•s, osmolality is 239 – 376 mOsm/kg, pH is 6.4 – 7.6.

Pregnancy

Do not use Armaviscon® Chondro during pregnancy and breastfeeding.

Contraindications

– increased sensitivity to product components;
– presence of active inflammatory or infectious processes in the joint;
– the presence of infection or damage, or signs of active skin disease in the area of ​​the intended injection;
– use in patients diagnosed with an autoimmune disease or undergoing immunotherapy;
– acute synovitis;
– pregnancy and breastfeeding period;
– age up to 18 years.

Side Effects

Moderate pain, swelling, increased temperature and redness in the injection area, and an increase in exudate in the joint cavity may occur. The above symptoms are transient and usually disappear after 72 hours. If these symptoms occur, it is recommended to unload the affected joint and apply ice.

Interaction

Armaviscon® Chondro should not be prescribed simultaneously with other intra-articular injections due to the lack of significant experience.

Prescribing

Area of ​​application: orthopedics, rheumatology, traumatology, surgery, sports medicine.
Armaviscon® Chondro is a synovial fluid prosthesis of the joint in pre-filled syringes. It is used against the background of degenerative changes in the surface of synovial cartilage to improve joint mobility, reduce pain, reduce inflammatory reactions and restore homeostasis in the cartilage.

Action

Armaviscon® Chondro has an analgesic, corrective effect on the metabolism of bone and cartilage tissue – helps normalize metabolic processes in bone and cartilage tissue, improves the nutrition of cartilage.
The product is a sterile viscous solution of the sodium salt of hyaluronic acid (sodium hyaluronate) of high purity, high molecular weight (molecular weight is not less than 0.9 MDa). Hyaluronic acid is an essential component of the extracellular matrix and is present in high concentrations in cartilage and synovial fluid. Hyaluronic acid provides viscosity and elasticity to synovial fluid, and is also necessary for the formation of cartilage. It forms a covering layer on the entire inner surface of the joint that protects the cartilage and synovial membrane from mechanical damage, as well as from free radicals and inflammatory factors. Intra-articular injection of hyaluronic acid leads to an improvement in the functional state of the joint.
Hyaluronic acid prevents friction of articular surfaces, which eliminates pain and inflammation, and also protects against premature wear and destruction of hyaline cartilage, ensures mobility, and has shock-absorbing capabilities (dampens external shocks, protecting joint components from damage).
Chondroitin sulfate is one of the naturally occurring glycosaminoglycans, consisting of the alternative sugar D-glucuronic acid and N-acetyl-D-galactosamine.
Chondroitin sulfate is a stimulator of tissue regeneration, promotes water retention and restoration of shock-absorbing functions in cartilage tissues. Promotes the synthesis and protection of collagen, which is the structural basis of all connective tissues, and also increases the production of hyaluronic acid in synovial cells, which has a beneficial effect on maintaining the viscosity of synovial fluid.
The use of chondroitin sulfate together with sodium hyaluronate helps slow down degradation and stimulate cartilage regeneration.
Removal or replacement of synovial fluid prosthesis is not applicable, since it is inseparably mixed with the synovial fluid of the joint.
Armaviscon® Chondro is intended to replenish the volume and restore the viscosity of synovial fluid in the joints. Armaviscon® Chondro dissolves in synovial fluid, providing a beneficial effect. It undergoes local transformations in the joint cavity, normalizes the properties of synovial fluid, restoring its lubricating and shock-absorbing functions.
Armaviscon® Chondro, with a single injection, restores the lubricating and shock-absorbing properties of the synovial fluid, which makes it possible to obtain a pronounced and long-term analgesic effect, since the limitation of joint mobility is significantly reduced.
Based on a review of studies of products with a similar composition, the duration of the therapeutic effect is up to 6 months or more, depending on the site of administration and the degree of the disease. If necessary, it is possible to carry out a second course of injections after consultation with a doctor.

Storage conditions

Store at temperatures from + 2 °C to + 25 °C. Do not freeze.
Keep out of the reach of children.

Shelf life

2 years.
Do not use after the expiration date!

Manufacturer

Grotex LLC, Russia